Ftse Mib
34.571,62
-0,30%
DAX
19.147,85
-0,54%
S&P 500
5.720,96
-0,14%
NASDAQ
18.219,19
-0,11%
Bitcoin
67.754,53
-1,44%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSXV Nurexone Biologic Inc (NRX) Nurexone Biologic Inc (NRX) Notizie

Nurexone Biologic Inc

NRX
0,68
0,01 (1,49%)
Ultimo aggiornamento: 17:05:45
Dati in Delay di 15 minuti
Borsa: TSX Venture
Tipo: Azione
Valuta: CAD

Ultime notizie

Data Ora Fonte Titolo
01/11/202421:50GLOBENurExone Biologic Closes Final Tranche of Non-Brokered..
23/10/202408:56GLOBENurExone’s Regenerative Medicine Therapies To Be Recognized..
26/9/202422:03GLOBENurExone Biologic Announces Private Placement of up to $2M..
12/9/202422:04GLOBENurExone Biologic Extends Global Reach with Presentations at..
06/9/202422:03GLOBENurExone Demonstrates Extended Therapeutic Window of ExoPTEN..
28/8/202414:34GLOBENurExone Reports Second Quarter 2024 Financial Results and..
23/8/202422:03GLOBENurExone Biologic Invited to Present Groundbreaking ExoPTEN..
15/8/202422:03GLOBENurExone Biologic Achieves Key Milestone in Support of..
09/8/202422:04GLOBENurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability..
01/8/202422:04GLOBENurExone Announces the Transfer of Manufacturing of the..
17/7/202422:14GLOBEPromising Preliminary Results in Optic Nerve Recovery Study..
05/7/202414:43GLOBEUpdates from NurExone: Growth Conference Presentation and..
28/6/202422:04GLOBENurExone’s ExoPTEN Being Studied as Glaucoma Treatment for..
21/6/202422:04GLOBEOn Path to First-in-Human Study, NurExone Engages Prominent..
11/6/202414:44GLOBENurExone Announces Expansion of ExoPTEN Patent Coverage with..
04/6/202422:40GLOBENurExone Announces Voting Results from 2024 Annual Meeting..
29/5/202414:35GLOBENurExone Reports First Quarter 2024 Financial Results and..
17/5/202422:04GLOBENurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive..
25/4/202417:30APSShares of Biopharma Up After News of Uplisting
25/4/202414:35GLOBENurExone Biologic Inc. Announces Strategic Expansion to US..
19/4/202422:04GLOBENurExone Presenting on Revolutionary Spinal Cord Injury..
02/4/202414:31GLOBENurExone Reports Fourth Quarter and Year Ended December 31,..
27/3/202422:05GLOBEGross Proceeds Close of $4M CAD Generated for NurExone From..
22/3/202422:04GLOBEIn Preparation for Expected Human Clinical Trials, NurExone..
15/3/202421:05GLOBENurExone's Strategic Update: Submission of OTCQB Listing..
08/3/202422:05GLOBENurExone establishing State-of-the-Art Research and..
01/3/202422:04GLOBENurExone Presenting Novel Regulatory Pathways for Exosomes..
20/2/202422:05GLOBENurExone’s Intellectual Property Portfolio Expands
14/2/202422:20GLOBENurExone Launches Licensing Efforts for ExoTherapy Platform
02/2/202422:05GLOBENurexone Biologic Initiates European Orphan Drug Designation..
17/1/202414:34GLOBENurExone and Inteligex Kick Off Chronic Spinal Cord Injury..
05/1/202414:30GLOBENurExone Announces Closing of a Private Placement for Gross..
29/11/202314:30GLOBENurExone Biologic Extends Spinal Cord Injury Therapy..
24/11/202314:30GLOBENurExone Reports Third Quarter 2023 Financial Results and..
16/11/202322:21APSTake Part in the Next Generation of Spinal Cord Injury..
07/11/202322:01APSOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap..
Apertura: 0,67 Min: 0,67 Max: 0,68
Chiusura: 0,67

La tua Cronologia

TSXV
NRX
Nurexone Biologic
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network